GlassScriptPhysician profile
Anthony D'Onofrio
NPI 1790248045
$1,162.88
in general payments reported to CMS, 2019-2025
17 companies · $828 in 2025
The $828 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.64 · 2023: $19.16 · 2024: $282 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $252.13 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $130.71 | 2025 | Zepbound, Mounjaro, Kisunla |
| Glaxosmithkline, LLC. | $96.85 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $84.64 | 2019-2025 | Gardasil 9, Capvaxive |
| Pfizer INC. | $82.96 | 2024-2025 | |
| Abbott Laboratories | $80.31 | 2024-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.09 | 2024-2025 | Jardiance |
| Eisai INC. | $59.42 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $49.36 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $42.27 | 2024-2025 | Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.32 | 2025 | Relistor, Xifaxan |
| Hydrocision, INC. | $40.74 | 2024 | Tenjet |
| Aimmune Therapeutics, INC. | $39.58 | 2025 | Zenpep |
| Seqirus USA INC | $25.88 | 2025 | Flucelvax, Fluad |
| Boston Scientific Corporation | $24.78 | 2025 | Watchman |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $19.31 | 2025 | Nexletol |
| Exact Sciences Corporation | $18.53 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony D'Onofrio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.